Prevail Therapeutics

Prevail Therapeutics

Prevail Therapeutics is a New York City-based biotechnology company and a wholly owned subsidiary of Eli Lilly and Company.

Prevail Therapeutics is developing gene therapies intended to target the root genetic causes of Parkinson's disease and other neurodegenerative disorders. The company's goal is to develop these gene therapies through advances in human genetics and gene therapy technology.

Timeline

March 2019
Prevail Therapeutics raises a $50,000,000 series B round from Surveyor Capital, Pontifax Venture Capital, RA Capital Management, EcoR1 Capital, Boxer Capital, OrbiMed, Adage Capital Management, AbbVie Inc., Omega Funds and Biotechnology Value Fund.
March 8, 2018
Prevail Therapeutics raises a $75,000,000 series A round from EcoR1 Capital, Pontifax Venture Capital, RA Capital Management, Boxer Capital, OrbiMed, Alexandria Venture Investments, Adage Capital Management, Omega Funds and Biotechnology Value Fund.
August 1, 2017
Prevail Therapeutics raises a $4,000,000 seed round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Prevail Therapeutics funding round, March 2019
50,000,000
March 2019
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Phil Taylor
December 15, 2020
FierceBiotech
Eli Lilly has joined the ranks of big pharma companies building a position in gene therapy, paying $26.50 per share to take control of New York-based Prevail Therapeutics and its two clinical-stage development programs.
Eli Lilly and Company
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.